Press Release

View printer-friendly version Back

Lantheus Medical Imaging, Inc. Announces Appointment of Dana S. Washburn, M.D., as Vice President, Clinical Development and Medical Affairs

-- New Addition to Lantheus Management Team Reinforces Company’s Commitment to
Product Pipeline Development and Patient Safety --

N. BILLERICA, Mass. (April 22, 2010)Lantheus Medical Imaging, Inc., a worldwide leader in diagnostic imaging, announced today the appointment of Dana S. Washburn, M.D., F.A.C.C, to the newly created position of Vice President, Clinical Development and Medical Affairs. Dr. Washburn brings to Lantheus 15 years of rich leadership experience in cardiology, medical device and diagnostics. He was most recently Vice President, Clinical Trials and Safety, and Medical Safety Officer at Boston Scientific Corporation.

In his new role, Dr. Washburn will be responsible for spearheading the clinical investigation of Lantheus’ pipeline of novel diagnostic imaging agents and providing ongoing medical and safety support for the company’s existing portfolio, including products such as DEFINITY®, ABLAVAR® , Cardiolite® and TechneLite®. Dr. Washburn will be involved in product life cycle management, including clinical trial oversight and the safety and surveillance of marketed products. He will also lead the company’s medical affairs department.

 “Dana’s patient-oriented focus, combined with his proven track record in industry and deep cardiovascular imaging expertise make him an outstanding addition to Lantheus’ management team,” said Don Kiepert, President and CEO of Lantheus Medical Imaging. “His appointment as Vice President, Clinical Development and Medical Affairs reflects our ongoing commitment to ensuring the highest possible safety standards for our products and in progressing our innovative pipeline.”

“Lantheus provides me with a unique opportunity to broaden the application of my experience in clinical development and cardiovascular imaging across a spectrum of products and modalities,” said Dr. Washburn. “I look forward to leading the company’s clinical development efforts and in working to further develop its pipeline. Lantheus has exciting programs underway in PET cardiovascular imaging that are designed to improve the evaluation of coronary artery disease and heart failure. I believe Lantheus can continue to advance the field of diagnostic medical imaging and make meaningful improvements to patient treatment and care.”

Prior to joining Lantheus, Dr. Washburn was Vice President, Clinical Trials and Safety, and Medical Safety Officer at Boston Scientific Corporation, where he was responsible for medical safety and clinical trial operations for the company’s product portfolio. In 2008, he was appointed to the company’s Operating Committee. Prior to his eight-year tenure in positions of increasing responsibility at Boston Scientific, Dr. Washburn was a Cardiologist at the Framingham Heart Center, providing a wide range of cardiovascular patient care while also focusing on echocardiography and nuclear cardiology. He also served as Assistant Director of the Cardiovascular Hemodynamic and Imaging Laboratory at Tufts-New England Medical Center. Dr. Washburn received his medical degree from the University of Massachusetts Medical School and he is currently a Fellow of the American College of Cardiology.

About Lantheus Medical Imaging, Inc.
Lantheus Medical Imaging, Inc., a worldwide leader in diagnostic medicine for more than 50 years, is dedicated to creating and providing pioneering medical imaging solutions to improve the treatment of human disease. The company’s proven success in discovering, developing and marketing innovative medical imaging agents provides a strong platform from which to bring forward breakthrough new tools for the diagnosis and management of disease. Lantheus imaging products include the echocardiography contrast agent DEFINITY® Vial for (Perflutren Lipid Microsphere) Injectable Suspension, ABLAVAR® (gadofosveset trisodium), a first-in-class magnetic resonance agent indicated for the evaluation of aortoiliac occlusive disease in adults with known or suspected peripheral vascular disease, TechneLite® (Technetium Tc99m Generator), Cardiolite® (Kit for the Preparation of Technetium Tc99m Sestamibi for Injection), and Thallium 201 (Thallous Chloride Tl 201 Injection).  Lantheus has more than 600 employees worldwide with headquarters in North Billerica, Massachusetts, and offices in Puerto Rico, Canada and Australia.  For more information, visit